Considerations on Direct Antiviral Agent Therapy in Patients Having Chronic Hepatitis C from Constanta County

Stavar Angelica¹, Dumitru Irina-Magdalena², Rugina S²

¹ Constanta County Hospital, Clinic of Internal Medicine
² Faculty of Medicine, Constanta

Introduction: Direct-acting antiviral agents (DAA) have a direct action in chronic hepatitis C, their addition to the standard therapy with interferon alfa2 (IFN) and ribavirin (RBV) significantly improving the sustained virologic response (SVR) in this disease. Objective: The study analyses the results of triple therapy including DAA in terms of tolerability and efficiency.

Material and method: We selected a lot of 24 patients who concluded the DAA administration period, being in the period of finalization of standard therapy at the time of the study. In all the patients clinical and paraclinical assessment was performed including laboratory tests, fibroscan, echography, etc.

Results: The duration of the therapy consisting in association of DAA to the standard treatment was 3 months and led to a remarkable result represented by a high rate of negativation of viremia (83.3%). Among the adverse reactions recorded, the most important were: anemia 17 patients (70.8%), leucopenia 10 patients (41.6%), thrombocitopenia 14 patients (58.3%), hyperbilirubinemia 3 patients (12.5%); hyperuricemia 8 patients (33.3%), hypocalcemia 4 patients (16.6%), loss of weight 4 patients (16.6%), anal pruritus (16.6%); among the 24 patients, 2% did not exhibit any adverse reactions.

Conclusions: Despite of the various adverse reactions recorded, the triple therapy consisting in DAA added to the standard treatment proves its utility, and the high rates of sustained viral reaction justifies its utilization. It is necessary to increase the number of patients who benefit from the advantages of triple therapy, which, after becoming larger available, could become a new standard therapy in patients with viral chronic hepatitis.

Keywords: direct-acting antiviral agents, Hepatitis C virus, sustained virologic response

Introduction

More than 180 million people worldwide are infected with the chronic hepatitis C virus (HCV), a major cause of liver cirrhosis, whose life-threatening complications include liver failure, portal hypertension and hepatocellular carcinoma [1]. In patients infected with HCV genotype 1, the chances of a sustained virologic response (SVR) with the previous standard of care treatment (Peg-IFN-α + ribavirin) are only 40 - 50%. Triple therapy, with DAA in combination with Peg-IFN-α + ribavirin, is the new standard of care for chronic hepatitis C treatment in genotype 1-infected patients [2].

Two NS3-4A protease inhibitors (boceprevir and telaprevir) are highly potent and were approved in Europe and in the United States in 2011 in combination with pegylated interferon (IFN)-α and ribavirin for the treatment of chronic hepatitis C related to HCV genotype 1 [3].

Treatment with available direct-acting antiviral (DAA) drugs has increased sustained virologic response (SVR) rates in genotype 1 infection and shortened duration of therapy in many patients, but these agents have a low barrier to resistance. Initial monotherapy studies of these agents showed prompt suppression of viral activity and rapid emergence of resistance, requiring that they could be administered along with a interferon alfa and ribavirin to prevent resistance, 12 weeks and 24 weeks after stopping DAA treatment [3-4].

Objective

The study analyses the effect of triple therapy including DAA (Telaprevir for 12 weeks) in terms of tolerability and efficiency.

Material and method

A lot of 24 patients was included in the study, who have concluded the DAA administration period, being in the period of finalization of standard therapy at the time of the study. The study was conducted in accordance to the declaration of Helsinki.

Inclusion Criteria

– Patients with HCV infection, 18 years to 70 years.
– Patients with HCV infection, with F3-F4 fibrosis evaluated by liver biopsy or non-invasive staging assessments such as FibroScan, MR-Elastography, or FibroTest/FibroSure.
– Patient must have had a liver biopsy before screening.
(or between the screening and baseline visit), unless they had a contraindication for procedure or any evidence of portal hypertension not associated with cirrhosis. For patients who had a liver biopsy performed more than 2 years prior to screening or without a biopsy (in case of a contraindication or portal hypertension), a non-invasive staging assessment was required, such as FibroScan, MR-Elastography, or FibroTest/FibroSure, which should have not been older than 6 months prior to screening.

- Chronicity of hepatitis C virus (HCV) infection, as confirmed by one or both of the following: presence of anti-HCV antibody and/or HCV ribonucleic acid (RNA) at least 6 months prior to the screening visit and/or presence of fibrosis on biopsy.
- Genotype 1 HCV infection with plasma HCV RNA of >10,000 IU/mL (both confirmed at screening).
- Partial and Null Responders patients at previous treatment with PegIFN PegIFNα-2a or PegIFNα-2b in combination with ribavirin (RBV).
- Patient must have had at least 1 documented previous course of treatment with PegIFNα-2a or PegIFNα-2b in combination with ribavirin (RBV) (at least 12 weeks for null responder and 20 weeks for partial responder).
- Patients (male and female) will use double barrier of contraception, condoms and cervical capeline.

Exclusion Criteria

- Hepatic decompensation (impaired functioning of the liver), as indicated by significant laboratory abnormalities or other active diseases.
- No hepatoarcoma or other malignancies.
- Infection with Human Immunodeficiency Virus (HIV) or non genotype 1 hepatitis C.
- Liver disease not related to hepatitis C infection.
- Previous chronic hepatitis C treatment, other than PegIFN and RBV.
- Pregnancy or breastfeeding.

The patients were evaluated at screening visit in clinical (physical examinations) and paraclinical terms: laboratory tests (HLG, biochemical analysis, urine collection, virus C genotype), liver biopsy or fibroscan, echography, electrocardiogram.

Study assessments at each study visit (1, 2, 4, 6, 8, 12 weeks) included: blood (HLG, ALT, AST, BT, BD, lipid profile, uric acid, electrolytes) and urine collection for testing, electrocardiogram (ECG) assessments, physical examinations and pregnancy test for females.

Results

We enrolled 24 patients (16 male and 8 female, aged between 32-64 years, median age 48 years), known to have chronic hepatitis C, out of which 6 patients null responder and 18 partial responder, with F3-F4 fibrosis by META-VIR score (Table 1).

<table>
<thead>
<tr>
<th>Gender</th>
<th>M/F</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>32-64 years</td>
</tr>
<tr>
<td>Median 48 years</td>
<td></td>
</tr>
<tr>
<td>Response to previous treatment with PegIFN and RBV</td>
<td>null responder/partial responder</td>
</tr>
<tr>
<td>Fibrosis by META-VIR score</td>
<td>F3/F4</td>
</tr>
</tbody>
</table>

Table 1. Baseline characteristics

The duration of the therapy association with DAA (Telaprevir 2250 mg/day, 750 mg at every 8 hours after eating) to the standard treatment was 3 months, with remarkable virological results meaning that after the utilization of the triple therapy a high rate of undetectable viremia was recorded at W12 in 83.3% of patients, while only two patients had detectable viremia at W12.

Tolerability was variable. Among the adverse reactions recorded, most frequent were: anemia 17 patients (70.8%), leucopenia, 10 patients (41.6%), thrombocytopenia 14 patients (58.3%), hyperbilirubinemia 3 patients (12,5%); hyperuricemia 8 patients (33,3%), hypocalcemia 4 patients (16,6%), loss of weight 4 patients (16,6%), anal pruritus (16,6%); only 2% of patients did not present any remarkable adverse reactions (Fig. 1, Table 2).

The laboratory results recorded in the study population are presented in table 3.

In cases with severe anemia the dose of ribavirin was reduced to 600 mg/day, without interruption of Telaprevir treatment. No serious adverse events requiring discontinuation of therapy were reported.

Discussion

The standard of care for treatment of HCV genotype 1 changed since the approval of two new DAA drugs (telaprevir and boceprevir) for use in pegylated interferon-based and ribavirin-based triple therapy in 2011 [5]. Until 2011, the standard therapy with pegylated interferon and ribavirin produced an SVR rate of approximately 40–50% for genotype 1 after 24–48 weeks of therapy [6]. Experience has shown improved response rates and treatment
durations for many patients with genotype 1 HCV infection after DAA treatment, with SVR rates as high as 63–75% and reduction in duration of therapy by half for many patients. Telaprevir efficacy was initially proven in multiple large multicenter trials [7-10]. As in our study, viral response after 12 weeks of triple therapy was 70-80% in prior null responders or partial responders.

In all clinical trials, the most common drug reactions to Telaprevir were rash, pruritus, anemia, nausea, hemorrhoids, diarrhea, anorectal discomfort, dysgeusia (alteration of taste), fatigue, vomiting and anal pruritus [7-10]. Rash developed in 56% of study subjects and severe rash was reported in 4% of subjects who received Telaprevir combination therapy [7-10]. In our study, no patient presented any form of rash.

Regarding anemia, clinical trials reported that 36% of patients had hemoglobin values less than or equal to 10 g/dL while hemoglobin values less than 8.5 g/dL were reported in 14% of them, similar to observations in our study.

Anorectal events were reported in 29% of subjects treated with Telaprevir combination treatment. The majority of these anorectal events included hemorrhoids, anorectal discomfort, anal pruritus and rectal burning which were mild to moderate in severity [7-10]. In our study 4 patients (16.6%) had only anal pruritus which disappeared after the end of therapy.

Conclusions
Chronic HCV infection is a public health problem on both global and national level, predominantly affecting middle-age, socially and professionally active people. It requires involvement of specialists in the sense of a permanent optimization of therapy to maintain a well-balanced cost/efficiency. The triple therapy, with DAA added to the standard therapy, proves its utility despite the various adverse reactions recorded, the high rates of sustained viral reaction justifying its utilization.

Anemia is the most common adverse reaction and the patients in our study had the highest proportion of moderate form of anemia. Leucopenia was observed in the study in approximately 40% of patients, being predominantly mild and without notable implications on therapy.

Thrombocytopenia was present in 50% of patients, predominantly mild form which did not require any adjustment in the interferon dose.

References

Table 2. Adverse reactions

<table>
<thead>
<tr>
<th>Legend</th>
<th>Adverse reaction</th>
<th>Mild</th>
<th>Medium</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>anemia</td>
<td>5 patients (20.8%)</td>
<td>8 patients (47%)</td>
<td>4 patients (24%)</td>
</tr>
<tr>
<td>2</td>
<td>leucopenia</td>
<td>7 patients (70%)</td>
<td>3 patients (30%)</td>
<td>0</td>
</tr>
<tr>
<td>3</td>
<td>thrombocytopenia</td>
<td>9 patients (64%)</td>
<td>5 patients (36%)</td>
<td>0</td>
</tr>
<tr>
<td>4</td>
<td>hyperbilirubinemia</td>
<td>3 patients (12.5%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>hyperuricemia</td>
<td>3 patients (12.5%)</td>
<td>0</td>
<td>5 patients, (63%)</td>
</tr>
<tr>
<td>6</td>
<td>hypocalcemia</td>
<td>2 patients (50%)</td>
<td>0</td>
<td>2 patients (50%)</td>
</tr>
<tr>
<td>7</td>
<td>loss of weight</td>
<td>4 patients (16.6%)</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>8</td>
<td>anal pruritus</td>
<td>4 patients (16.6%)</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Table 3 – Laboratory results in the study population

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Adverse reaction</th>
<th>Mild</th>
<th>Medium</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hgb</td>
<td>anemia</td>
<td>10.0–10.9 g/dL</td>
<td>9.99–9.9 g/dL</td>
<td>7.0–8.3 g/dL</td>
</tr>
<tr>
<td>WBC</td>
<td>leucopenia</td>
<td>2.000–2500/mm³</td>
<td>1500–1999/mm³</td>
<td>1000–1499/mm³</td>
</tr>
<tr>
<td>Platelets</td>
<td>thrombocytopenia</td>
<td>100.000–124999/mm³</td>
<td>50.000–99999/mm³</td>
<td>25000–49999/mm³</td>
</tr>
<tr>
<td>Total bilirubin</td>
<td>hyperbilirubinemia</td>
<td>&gt;/= 1.1 to &lt;1.5xULN</td>
<td>&gt;/= 2.5 to &lt;5.00xULN</td>
<td>&gt;/= 5.00xULN</td>
</tr>
<tr>
<td>Uric acid</td>
<td>hyperuricemia</td>
<td>7.5–10.0mg/dL</td>
<td>7.0–7.7mg/dL</td>
<td>12.1–15.0mg/dL</td>
</tr>
<tr>
<td>Calcium</td>
<td>hypocalcemia</td>
<td>7.8–8.4mg/dL</td>
<td>7.8–8.4mg/dL</td>
<td>6.1–6.9mg/dL</td>
</tr>
<tr>
<td>Body weight</td>
<td>loss of weight</td>
<td>5–9% loss in body weight from baseline</td>
<td>10–19% loss in body weight from baseline</td>
<td>&gt;19% loss in body weight from baseline</td>
</tr>
</tbody>
</table>